

# ATW HOLDINGS LTD

ACN 100 531 191

## ASX Release

11 February 2013

The Company Announcements Office  
ASX Ltd  
*via electronic lodgement*

### FITGENES SHARE PURCHASE TRANSACTION STATUS UPDATE

The Directors of ATW Holdings Limited (ASX: ATW) ("Company") provide the following update on the status of the Proposed Transaction with Fitgenes Pty Ltd ("Fitgenes") to acquire 100% ownership of Fitgenes. This transaction was first announced to the market on 01 November 2011 and was subject to a number of conditions precedent, most of which have now been satisfied - the remaining process is to seek the approval of the Company's shareholders and regulatory authorities.

As announced to the market on 15 February 2012 the ASX ruled that the Proposed Transaction will require the Company to re-comply with Chapters 1 and 2 of the listing rules of the Australian Securities Exchange. Since that date the Company has completed an Entitlement Offer to fund ongoing operating costs, and Fitgenes has completed an interim raise to fund the capital raising process required for the Company to re-comply with the listing rules.

Since closure of the ATW Entitlement Offer and the Fitgenes interim round during September 2012, the Directors of both companies have been preparing documentation and preparing for the issuing of a Prospectus during the quarter ending 30 June 2013. This process has included identifying and assessing further assets for acquisition that are synergistic with the Fitgenes business in support of that company's expansion strategies for Australia, Asia, Europe, the UK and America.

With respect to Fitgenes' ongoing operations in the lead up to the release of the ATW Prospectus, the company has:

- continued its geographic expansion to now include New Zealand and Hong Kong;
- extended its product offering into pathology services; and
- commercialised two new gene panels.

Fitgenes is now poised to release its proprietary HTML based gene diagnostic and practice management software to its Certified Practitioners across Australia, New Zealand, Singapore, Malaysia and Hong Kong.

Fitgenes is celebrating this software release by launching the most advanced and comprehensive Women's Health Program available utilizing genetic profiling. This will comprise a 16 week controlled program including pathology and ongoing nutrigenomics, nutritional, and lifestyle interventions. The program will initially be delivered via flagship allied health practices and GP clinics across Australia prior to a staged rollout into other markets. Further details will be released by Fitgenes at [www.fitgenes.com](http://www.fitgenes.com).

As a result of all this work and progress, your Directors believe that the value of the Fitgenes business has increased markedly. This in turn will benefit all ATW shareholders through reduced dilution.

In closure, your Directors thank you for your ongoing support and patience while the Company and Fitgenes prepare for the re-compliance process and we will continue to keep you informed as milestones are reached.

For further particulars please contact:

Robert Mair  
Director  
ATW HOLDINGS LIMITED  
+61 (0) 416 190 273 (mobile)